

GATRA

Grifols Antithrombin Research Awards



GATRA

Grifols Antithrombin Research Awards

THE GATRA PROGRAM

The Grifols Antithrombin Research Awards (GATRA) program's objective is to identify and support research projects on current and new uses of antithrombin as a therapeutic product, thereby helping to improve standards of care and quality of life for patients. Further goals are to establish new and long-lasting cooperation with participating scientists and clinicians, strengthen and expand the existing network between researchers and the company, and foster relationships with key opinion leaders in different fields.

ABOUT THE GATRA PROGRAM

Grifols is a global biotherapeutic and biotechnology company that discovers, develops, and produces treatments and services for patients with antithrombin deficiency. Proposals may include, but are not limited to: efficacy, mechanism of action, safety and tolerability, quality of life, and pharmacoeconomics.

The GATRA program offers 1 award of €50,000 to applicants whose proposals best match the program objectives, according to assessment by an independent review committee.

The GATRA Program aims to:

- Develop novel concepts in antithrombin research
- Encourage discovery of beneficial antithrombin applications
- Further investigate mechanisms of action
 or clinical effects in different indications

WHO CAN APPLY

Scientists or clinicians with an innovative idea to gain more insight into the uses of antithrombin. Applications are encouraged from both individuals and teams who may be undertaking research at hospitals, universities, or independent institutions.

Applicants to the GATRA program must:

- Present a focused project with goals that can be achieved within 12 months
- Be employed or supported by an institution

REVIEW BOARD

Marcel Levi (Chair)

Chief Executive, University College London Hospitals Professor of Medicine, University College London, UK Professor of Medicine, University of Amsterdam, The Netherland

Javier Corral

Professor of Internal Medicine Department of Internal Medicine University of Murcia Centro Regional de Hemodonación IMIB-Arrixaca Murcia, Spain

Wulf Dietrich

Professor of Anesthesiology Departments of Anesthesiology and Transfusion Medicine Institute for Research in Cardiac Anesthesia Munich, Germany

Satoshi Gando

Advisor and Director Acute and Critical Care Center Department of Acute and Critical Care Medicine Sapporo Higashi Tokushukai Hospital Sapporo, Japan

Jerrold H. Levy

Professor of Anesthesiology Associate Professor of Surgery Codirector of Cardiothoracic ICU Department of Anesthesiology of Cardiac Division Duke University School of Medicine Durham, NC, USA

Ida Martinelli

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan, Italy

George M. Rodgers III

Professor of Medicine and Pathology University of Utah Health Sciences Center Director of Coagulation Laboratory ARUP Laboratories Salt Lake City, UT, USA

Maria Aurelia Ricci

(non-voting Executive Secretary) Manager Medical Affairs - Intensive Care -EU/ROW. Grifols S.A. Sant Cugat del Vallés (Barcelona), Spain

TIMELINES FOR THE GATRA PROGRAM

Letter of intent submission: **Every year** from November 1st to April 30th

Awardee announcement: July

Additional information on the grant program, detailed timelines, the constitution of the review board and the application process can be found on our website: www.grifols.com or www.grifolsscientificawards.com



EVALUATIONS AND SELECTION OF RESEARCH PROPOSALS

Applications are evaluated based on merit, innovation, impact, and research environment/qualification of the applicant. A review board of external experts in antithrombin assess and rank the grant applications.

GRIFOLS SCIENTIFIC AWARDS













Award for Scientific Progress in Immunodeficiency Research

GRIFOLS